Folate (Methylfolate / 5-MTHF)
SupplementThe medical score is higher because clinical evidence for folate deficiency prevention and homocysteine reduction is very robust [s6, s7, s9], whereas the community is polarized — a relevant proportion reports overmethylation symptoms and adjustment difficulties that are not prominent in RCTs [c2, c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Methylfolate (5-MTHF) is among the best-evidenced supplements available: WHO-recommended for neural tube defect prevention, superior homocysteine reduction vs. folic acid in RCTs, and clinically meaningful as an antidepressant augmentation strategy. Always check vitamin B12 status before starting — undiagnosed B12 deficiency can be masked by folate, with serious neurological consequences. A meaningful minority of users experience anxiety and overstimulation, reflecting significant individual variation in methylation capacity. Use with caution in bipolar disorder without psychiatric supervision.
Description
Biologically active folate form requiring no MTHFR conversion; supports methylation, homocysteine reduction, pregnancy health, and cognitive function [s1, s3, s6].
Folate is a water-soluble B vitamin (B9) that occurs in food as polyglutamate and is cleaved in the intestine to monoglutamate folate. Synthetic folic acid (pteroylmonoglutamic acid) must be converted in the body via several enzymatic steps — including the enzyme methylenetetrahydrofolate reductase (MTHFR) — into the biologically active form 5-methyltetrahydrofolate (5-MTHF) [s1, s3]. 5-MTHF (methylfolate) bypasses these conversion steps entirely and is directly available for metabolism [s3]. This is particularly relevant for individuals with the common MTHFR C677T polymorphism, in which enzyme activity can be reduced by up to 70%, significantly slowing the conversion of folic acid [s2, s4]. Primary functions of folate in the body: - Prevention of neural tube defects (NTDs) in early pregnancy [s6, s7, s8] - Homocysteine reduction via remethylation to methionine [s5, s9] - Support of DNA synthesis, cell division, and hematopoiesis [s11] - Role in neurotransmitter synthesis (serotonin, dopamine, noradrenaline) via the methylation cycle [s10] Multiple studies show that 5-MTHF lowers homocysteine levels more effectively than equivalent doses of folic acid [s5]. The bioavailability of 5-MTHF as a glucosamine salt (Quatrefolic®) was described in one study as 3.1-fold higher than folic acid [s1]. In gastrointestinal absorption disorders, absorption of 5-MTHF remains largely intact, as conversion does not depend on the intestinal environment [s3]. In psychiatry, L-methylfolate is being investigated as an augmentation strategy in treatment-resistant depression, as folate deficiency is associated with reduced monoamine synthesis [s10].
Legal Status (DE)
Folate (as calcium L-methylfolate, 5-MTHF glucosamine, or 5-MTHF sodium salt) is approved in the EU as a folate source in food supplements under Regulation (EC) No. 1170/2009 and is marketable in Germany as an OTC supplement [s12, s13]. The BfR recommends a maximum of 400 µg folate equivalents per day in supplements [s12].
Mechanism of Action
5-MTHF is the only folate metabolite that crosses the blood-brain barrier and directly participates in cellular methylation reactions [s3, s10]. Core mechanism — methylation cycle: 5-MTHF donates a methyl group to homocysteine, producing methionine and tetrahydrofolate (THF). This reaction is catalyzed by methionine synthase (MS) and requires vitamin B12 as a cofactor [s2, s3]. Methionine is further activated to S-adenosylmethionine (SAM), the universal methyl group donor for over 200 methylation reactions, including DNA methylation, histone modification, and neurotransmitter synthesis [s10]. Neurotransmitter synthesis: SAM is a cofactor for the conversion of L-DOPA to dopamine and for the synthesis of serotonin and noradrenaline. Folate deficiency reduces SAM availability and thereby monoamine synthesis — a mechanistic link to depression [s10]. DNA synthesis: THF (from the MS reaction) is required for the synthesis of purines and thymidine, which are essential for DNA replication and repair. This explains the importance of folate for rapidly dividing cells (hematopoiesis, embryonic development) [s11]. MTHFR polymorphism: In MTHFR C677T carriers, the reduction of 5,10-methylene-THF to 5-MTHF is impaired. Direct supplementation with 5-MTHF bypasses this bottleneck entirely [s2, s4]. B12 masking risk: High folate doses can correct the hematological signs of B12 deficiency (megaloblastic anemia) while neurological damage from B12 deficiency progresses undetected — a well-known clinical risk [s14].
Dosing
Neuralrohrdefekt-Prävention (Schwangerschaft/Kinderwunsch)
- Dose
- 400 µg folate equivalents (as 5-MTHF or folic acid)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- Ab 4 Wochen vor Konzeption bis Ende 12. SSW
- Timing
- Daily, independent of meals
- With food
- optional
Homocysteinsenkung / MTHFR-Polymorphismus
- Dose
- 400–800 µg 5-MTHF daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- Langfristig, ärztliche Kontrolle empfohlen
- Timing
- Morning with a meal
- With food
- empfohlen
Augmentation bei Depression (psychiatrischer Kontext)
- Dose
- 7.5–15 mg L-methylfolate daily (prescription-only in the USA as Deplin®)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- Mindestens 12 Wochen, unter ärztlicher Aufsicht
- Timing
- Morning
- With food
- empfohlen
Allgemeine Folatversorgung / Basisschutz
- Dose
- 200–400 µg folate equivalents daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- Dauerhaft möglich
- Timing
- Any time
- With food
- optional
The BfR recommends a maximum of 400 µg folate equivalents per day from supplements for adults [s12]. EFSA has confirmed safe use of calcium L-methylfolate up to 1 mg/day [s13]. For high-dose psychiatric protocols (up to 15 mg), medical supervision is mandatory [s10].
Vitamin B12 status should be assessed before initiating folate therapy to rule out the masking risk [s14]. MTHFR genotyping may be advisable in cases of family planning or recurrent miscarriages [s4].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Maskierung eines Vitamin-B12-Mangels (hämatologisch, nicht neurologisch) High folate doses can correct megaloblastic anemia caused by B12 deficiency while subacute combined degeneration of the spinal cord progresses undetected [s14]. | theoretisch | schwer |
| Angst, innere Unruhe, Überstimulation (Übermethylierung) Described particularly at higher doses (≥5 mg) and with rapid dose escalation; community reports indicate relevant frequency [c1, c4]. | gelegentlich | moderat |
| Schlafstörungen, Reizbarkeit Due to increased SAM availability and monoamine turnover; repeatedly reported in user forums [c1, c3]. | gelegentlich | leicht |
| Gastrointestinale Beschwerden (Übelkeit, Blähungen) Less common than with folic acid; even less frequent with enteric-coated formulations [s3]. | selten | leicht |
| Bipolare Episode (theoretisch bei prädisponierten Personen) Increased methylation capacity and monoamine activity can trigger manic episodes; caution in patients with known bipolar disorder [s15]. | theoretisch | schwer |
| Allergische Reaktion Rare hypersensitivity reactions to excipients or carriers (e.g., glucosamine salts from shellfish sources) are possible [s13]. | selten | moderat |
Contraindications
Folate administration without concurrent B12 therapy masks hematological symptoms and allows progression of irreversible neuropathy [s14].
Methylfolate may trigger manic episodes via increased monoamine synthesis; high-dose therapy only under psychiatric supervision [s15].
Folate antagonizes the antiproliferative effect of methotrexate; in low-dose MTX (rheumatology), folate is conversely used to reduce adverse effects — the indication is decisive [s16].
Methylfolate may reduce plasma levels of phenytoin, carbamazepine, primidone, and valproate, thereby compromising seizure control [s15].
Interactions
Synergistic
B12 is an essential cofactor of methionine synthase; the combination optimizes homocysteine degradation and prevents masking risk [s2, s9].
B6 is a cofactor in the transsulfuration pathway (homocysteine → cysteine); the triple combination B9+B12+B6 demonstrates maximal homocysteine reduction [s9].
Synergistic support of the methylation cycle and neurotransmitter synthesis; combined in psychiatric protocols [s10].
TMG supports the conversion of homocysteine to methionine via the BHMT pathway, independently of the methylfolate-dependent pathway. The combination relieves the methylation cycle and provides redundant homocysteine lowering.
Choline is oxidized to betaine in the liver, thereby supporting the BHMT methylation pathway. Choline and folate interact at the point of homocysteine remethylation and can mutually compensate for each other.
Caution
Folate antagonizes the mechanism of action of MTX; concomitant use may reduce therapeutic efficacy [s16].
Methylfolate may lower plasma levels of these antiepileptics and increase seizure risk; therapeutic drug monitoring recommended [s15].
Folinate/folate potentiates 5-FU toxicity by stabilizing the ternary complex with thymidylate synthase [s16].
Methylfolate may affect levodopa absorption; a minimum interval of 2 hours is recommended [s15].
High-dose folic acid/folate supplementation may inhibit intestinal zinc absorption, possibly through formation of insoluble chelates. At moderate doses, however, the effect is of limited clinical relevance according to more recent studies.
Studies
Tier A — High Evidence
Outcome: Benefits and harms of periconceptional folic acid supplementation
Effect Size: Strong evidence for NTD prevention; 5-MTHF discussed as equivalent alternative
Outcome: Homocysteine lowering: 5-MTHF vs. folic acid
Effect Size: 9.3% reduction with folic acid vs. 14.6% with 5-MTHF
Outcome: Prevention of neural tube defects
Effect Size: Significant reduction in NTD risk with periconceptional folate supplementation
Outcome: Reduction of total homocysteine levels (tHcy)
Effect Size: Both forms (folinic acid vs. L-methylfolate) significant; 5-MTHF numerically superior
Tier B — Moderate Evidence
Outcome: Comparison of active folates vs. folic acid; bioavailability, MTHFR relevance
Effect Size: 5-MTHF (Quatrefolic®) showed 3.1× higher plasma levels vs. folic acid in bioavailability comparison
Outcome: Metabolic differences between folate / folic acid / 5-MTHF; MTHFR polymorphism
Effect Size: 5-MTHF superior under gastrointestinal pH alterations and MTHFR defects
Outcome: Depression reduction and medication satisfaction with L-methylfolate
Effect Size: Significant improvement in depression severity (PHQ-9)
Tier C — Low Evidence
Outcome: Folate supplementation in MTHFR mutations; treatment options
Effect Size: Mechanistic analysis; no direct effect sizes
Community Evidence
Top reported benefits
- Improved mood and drive (particularly in MTHFR mutation carriers)
- Reduction of anxiety symptoms with chronic use
- Improved cognitive clarity and concentration
- Superior efficacy compared to folic acid in known MTHFR variants
- Reduction of elevated homocysteine levels
Top reported issues
- Anxiety and inner restlessness at initiation or high doses
- Sleep disturbances, irritability with overmethylation
- Adjustment phase of 2–4 weeks with transient side effects
- High interindividual variation in optimal dose
A relevant portion of the community reports strong adverse reactions to methylfolate, referred to as "overmethylation." Many of these reports originate from r/MTHFR [c2, c4]. Forum experts note that products containing multiple B vitamins with only trace amounts of methylfolate are often incorrectly attributed as the cause [c2]. The polarization of reports suggests strong individual differences in methylation status.
Scientific Sources
- Active Folate Versus Folic Acid: The Role of 5-MTHF (Methylfolate) in Human Health
Greenberg JA, Bell SJ, Ausdal WV, et al. (2011). Journal of Midwifery & Women's Health / PMCBLink - Assessing Effects of l-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial
Shelton RC, Sloan Manning J, Barrentine LW, et al. (2013). Primary Care Companion for CNS Disorders / PMCBLink - Folate related health claims — EFSA Scientific Opinion
EFSA NDA Panel (2010). EFSA JournalADOI - Aktualisierung 2024: Höchstmengenvorschläge für Folsäure in Lebensmitteln inklusive Nahrungsergänzungsmitteln — BfR Stellungnahme 009/2024
Bundesinstitut für Risikobewertung (BfR) (2024). BfRALink - Safety of monosodium salt of l-5-methyltetrahydrofolic acid as a novel food — EFSA Opinion 2023
EFSA NDA Panel (2023). EFSA JournalALink - What are the risks and precautions of supplementing L-methylfolate in adults, including concerns about vitamin B12 deficiency
DrOracle Medical Editorial (2024). DrOracle.aiCLink - Methylfolat Plus — Produktinformation und Warnhinweise
Energetica Natura (2024). Energetica Natura ProduktdatenbankCLink - Methotrexat — Anwendung, Wirkung, Nebenwirkungen, Wechselwirkungen
Gelbe Liste Redaktion (2024). Gelbe ListeBLink - Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats
Miraglia N, Dehning M, Swickrath E, Meyer T, Gnosis SpA (2016). Journal of Nutritional Science and VitaminologyCPMID:27008238 - No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study
Hvas AM, Juul S, Lauritzen L, Nexo E, Ellegaard J (2024). C - Folic Acid, Folinic Acid, 5 Methyl TetraHydroFolate Supplementation for Mutations That Affect Epigenesis through the Folate and One-Carbon Cycles
Menezo Y, Clement A, Clement P, et al. (2022). Biomolecules (MDPI) / PMCBDOI - Folate, folic acid and 5-methyltetrahydrofolate are not the same thing
Scaglione F, Panzavolta G (2014). XenobioticaBPMID:24494987DOI - L-Methylfolate vs. Folic Acid Supplements for MTHFR C677T
GeneSight Medical Team (2023). GeneSight White PaperCLink - 5-MTHF vs. Folic Acid: Homocysteine Reduction (24-week placebo-controlled study)
Life Extension Medical Editorial Team (citing primary study) (2016). Life Extension MagazineCLink - Effects and safety of periconceptional oral folate supplementation for preventing birth defects
De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, et al. (2015). WHO ELENA / Cochrane DatabaseALink - Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Viswanathan M, Treiman KA, Kish-Doto J, et al. (2023). JAMAADOI - Supplementation with Folic Acid or 5-Methyltetrahydrofolate and Prevention of Neural Tube Defects: An Evidence-Based Narrative Review
Obeid R, Holzgreve W, Pietrzik K, et al. (2024). PubMed / NutrientsBPMID:39339754 - The effects of folinic acid and l-methylfolate supplementation on serum total homocysteine levels in healthy adults
Lambropoulos A, Chroni E, Tsamis K, et al. (2023). PubMed (Nutrients or similar)APMID:38056998
Community Sources
Storage
Unopened
Store in a dry, cool place (below 25 °C), protected from light.
Opened
Keep container tightly closed; avoid moisture. Powder forms are particularly sensitive.
Notes
5-MTHF is more light-sensitive than synthetic folic acid; dark or opaque packaging is preferred.